Home Oxygen After Hospitalization for COVID-19 : Results From the Multi-Center OXFORD Study
Copyright © 2024 by Daedalus Enterprises..
BACKGROUND: In the first months of the pandemic, prior to the introduction of proven-effective treatments, 15-37% of patients hospitalized with COVID-19 were discharged on home oxygen. After proven-effective treatments for acute COVID-19 were established by evidence-based guidelines, little remains known about home oxygen requirements following hospitalization for COVID-19.
METHODS: This was a retrospective, multi-center cohort study of subjects hospitalized for COVID-19 between October 2020-September 2021 at 3 academic health centers. Information was abstracted from electronic health records at the index hospitalization and for 60 d after discharge. The World Health Organization COVID-19 Clinical Progression Scale score was used to identify patients with severe COVID-19.
RESULTS: Of 517 subjects (mean age 58 y, 47% female, 42% Black, 36% Hispanic, 22% with severe COVID-19), 81% were treated with systemic corticosteroids, 61% with remdesivir, and 2.5% with tocilizumab. About one quarter of subjects were discharged on home oxygen (26% [95% CI 22-29]). Older age (adjusted odds ratio [aOR] 1.02 per 5 y [95% CI 1.02-1.02]), higher body mass index (aOR 1.02 per kg/m2 [1.00-1.04]), diabetes (yes vs no, aOR 1.73 [1.46-2.02]), severe COVID-19 (vs moderate, aOR 3.19 [2.19-4.64]), and treatment with systemic corticosteroids (yes vs no, aOR 30.63 [4.51-208.17]) were associated with an increased odds of discharge on home oxygen. Comorbid hypertension (yes vs no, aOR 0.71 [0.66-0.77) was associated with a decreased odds of home oxygen. Within 60 d of hospital discharge, 50% had documentation of pulse oximetry; in this group, home oxygen was discontinued in 46%.
CONCLUSIONS: About one in 41 subjects were prescribed home oxygen after hospitalization for COVID-19, even after guidelines established proven-effective treatments for acute illness. Evidence-based strategies to reduce the requirement for home oxygen in patients hospitalized for COVID-19 are needed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:69 |
|---|---|
| Enthalten in: |
Respiratory care - 69(2024), 3 vom: 28. Feb., Seite 281-289 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Freedman, Michael B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 29.02.2024 Date Revised 04.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4187/respcare.11436 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366675206 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366675206 | ||
| 003 | DE-627 | ||
| 005 | 20240404234539.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4187/respcare.11436 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM366675206 | ||
| 035 | |a (NLM)38176902 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Freedman, Michael B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Home Oxygen After Hospitalization for COVID-19 |b Results From the Multi-Center OXFORD Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.02.2024 | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 by Daedalus Enterprises. | ||
| 520 | |a BACKGROUND: In the first months of the pandemic, prior to the introduction of proven-effective treatments, 15-37% of patients hospitalized with COVID-19 were discharged on home oxygen. After proven-effective treatments for acute COVID-19 were established by evidence-based guidelines, little remains known about home oxygen requirements following hospitalization for COVID-19 | ||
| 520 | |a METHODS: This was a retrospective, multi-center cohort study of subjects hospitalized for COVID-19 between October 2020-September 2021 at 3 academic health centers. Information was abstracted from electronic health records at the index hospitalization and for 60 d after discharge. The World Health Organization COVID-19 Clinical Progression Scale score was used to identify patients with severe COVID-19 | ||
| 520 | |a RESULTS: Of 517 subjects (mean age 58 y, 47% female, 42% Black, 36% Hispanic, 22% with severe COVID-19), 81% were treated with systemic corticosteroids, 61% with remdesivir, and 2.5% with tocilizumab. About one quarter of subjects were discharged on home oxygen (26% [95% CI 22-29]). Older age (adjusted odds ratio [aOR] 1.02 per 5 y [95% CI 1.02-1.02]), higher body mass index (aOR 1.02 per kg/m2 [1.00-1.04]), diabetes (yes vs no, aOR 1.73 [1.46-2.02]), severe COVID-19 (vs moderate, aOR 3.19 [2.19-4.64]), and treatment with systemic corticosteroids (yes vs no, aOR 30.63 [4.51-208.17]) were associated with an increased odds of discharge on home oxygen. Comorbid hypertension (yes vs no, aOR 0.71 [0.66-0.77) was associated with a decreased odds of home oxygen. Within 60 d of hospital discharge, 50% had documentation of pulse oximetry; in this group, home oxygen was discontinued in 46% | ||
| 520 | |a CONCLUSIONS: About one in 41 subjects were prescribed home oxygen after hospitalization for COVID-19, even after guidelines established proven-effective treatments for acute illness. Evidence-based strategies to reduce the requirement for home oxygen in patients hospitalized for COVID-19 are needed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Long COVID | |
| 650 | 4 | |a SARS-CoV-2l | |
| 650 | 4 | |a durable medical equipment | |
| 650 | 4 | |a hypoxemia | |
| 650 | 4 | |a post-acute sequelae of SARS-CoV-2 | |
| 650 | 7 | |a Oxygen |2 NLM | |
| 650 | 7 | |a S88TT14065 |2 NLM | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 700 | 1 | |a Kim, Yoo Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Kaur, Ramandeep |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Bijal V |e verfasserin |4 aut | |
| 700 | 1 | |a Adegunsoye, Ayodeji O |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Yu-Che |e verfasserin |4 aut | |
| 700 | 1 | |a DeLisa, Julie A |e verfasserin |4 aut | |
| 700 | 1 | |a Gardner, Jessica M |e verfasserin |4 aut | |
| 700 | 1 | |a Gordon, Howard S |e verfasserin |4 aut | |
| 700 | 1 | |a Greenberg, Jared A |e verfasserin |4 aut | |
| 700 | 1 | |a Kaul, Malvika |e verfasserin |4 aut | |
| 700 | 1 | |a Khouzam, Nader |e verfasserin |4 aut | |
| 700 | 1 | |a Labedz, Stephanie L |e verfasserin |4 aut | |
| 700 | 1 | |a Mokhlesi, Babak |e verfasserin |4 aut | |
| 700 | 1 | |a Rintz, Jacob |e verfasserin |4 aut | |
| 700 | 1 | |a Rubinstein, Israel |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Analisa |e verfasserin |4 aut | |
| 700 | 1 | |a Vines, David L |e verfasserin |4 aut | |
| 700 | 1 | |a Ziauddin, Lubna |e verfasserin |4 aut | |
| 700 | 1 | |a Gerald, Lynn B |e verfasserin |4 aut | |
| 700 | 1 | |a Krishnan, Jerry A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory care |d 1974 |g 69(2024), 3 vom: 28. Feb., Seite 281-289 |w (DE-627)NLM07486520X |x 1943-3654 |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:2024 |g number:3 |g day:28 |g month:02 |g pages:281-289 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4187/respcare.11436 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 69 |j 2024 |e 3 |b 28 |c 02 |h 281-289 | ||